Harada Kazuto, Mizrak Kaya Dilsa, Shimodaira Yusuke, Ajani Jaffer A
Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd (FC10.3022), Houston, TX, 77030, USA.
Gastric Cancer. 2017 Mar;20(Suppl 1):92-101. doi: 10.1007/s10120-016-0655-8. Epub 2016 Oct 7.
To combat the dismal mortality rates from metastatic gastric adenocarcinoma (GAC), new drugs and treatment strategies are needed. Today, metastatic GAC is predominantly treated by empiric chemotherapy. Combination of two cytotoxic agents has become commonplace in North America, Europe, and Asia. Human epidermal growth factor 2 (HER2) overexpression (protein or gene copy numbers) has resulted in the addition of trastuzumab in the first-line chemotherapy combination in patients whose tumor is HER2 positive. The addition of trastuzumab in this select population has provided a modest survival advantage. In this review we trace the global development of systemic therapy in patients with metastatic GAC and ponder what lies in the future.
为了应对转移性胃腺癌（GAC）令人沮丧的死亡率，需要新的药物和治疗策略。如今，转移性GAC主要通过经验性化疗进行治疗。在北美、欧洲和亚洲，两种细胞毒性药物联合使用已变得很普遍。人表皮生长因子2（HER2）过表达（蛋白质或基因拷贝数）导致在肿瘤为HER2阳性的患者的一线化疗方案中加入曲妥珠单抗。在这一特定人群中加入曲妥珠单抗带来了适度的生存优势。在本综述中，我们追溯了转移性GAC患者全身治疗的全球发展历程，并思考未来的发展方向。
